Antiphospholipid Syndrome – Early Pregnancy Loss

2021 ◽  
pp. 585-590
Author(s):  
Neeta Thakur
Keyword(s):  
Deep Vein Thrombosis ◽  
Antiphospholipid Syndrome ◽  
Pregnancy Loss ◽  
Recurrent Pregnancy Loss ◽  
Annual Incidence ◽  
Obstetric Outcome ◽  
Immune Disorder ◽  
Vein Thrombosis ◽  
History Of ◽  
Deep Vein

Antiphospholipid syndrome (APLS) is an acquired is auto immune disorder that is defined by the presence of antibodies known as antiphospholipid antibodies in addition to clinical thrombosis and/ or poor obstetric outcome. Although the incidence remains unknown, 10% to 15% of women with a history of recurrent pregnancy loss will meet the criteria for APLS. In these Patients, the annual incidence of deep vein thrombosis and stroke is 1.46% and 0.32% respectively. Compared with the annual incidence in the general population of 0.1% for deep vein thrombosis and 0.1% for stroke.1

scholarly journals Frequency of Thrombophilic Gene Mutations in Patients with Deep Vein Thrombosis and in Women with Recurrent Pregnancy Loss

2017 ◽  
Vol 12 (1) ◽  
pp. 162-166 ◽  
Author(s):  
Mahmoud Mohamed Elgari ◽  
Nadir Ahmed Ibrahim ◽  
Abdel Rahim Mahmoud Muddathir ◽  
Faris Mergheni Eltoom ◽  
Ibrahim M Ibrahim
Keyword(s):  
Deep Vein Thrombosis ◽  
Protein C ◽  
Pregnancy Loss ◽  
Recurrent Pregnancy Loss ◽  
Factor V Leiden ◽  
Protein S ◽  
Prothrombin G20210a ◽  
Factor V ◽  
Vein Thrombosis ◽  
Deep Vein

AbstractThrombophilia may be anticipated by single or combined hereditary defects in encoding genes factor V, Prothrombin, and MTHFR. The aim of this study was to determine the prevalence and associated risks of V Leiden (G1691A), Prothrombin (G20210A), and MTHFR (C677T) mutations in Saudi women with Deep Vein Thrombosis (DVT) and women with recurrent pregnancy loss (RPL). Protein C and protein S activity were measured to determine combined effects, if any. We examined 60 women with a history of DVT and 60 with RPL, extracted DNA from EDTA blood and determined three mutations by using multiplex PCR reactions followed by Strip Assay KIT. Pro C Global assay was used to determine the cutoff value [PCATNR = 0.80]. Protein C/S chromogenic assay was used to estimate protein C and S percentages. Frequency of Factor V Leiden G/A genotype in patients with DVT 7 (11.6%) had a significant association for DVT χ2 (OR = 5.1, P = 0.03). In women with RPL the three mutations did not show any significant association, levels of Protein C, protein S and PCAT-NR in patient groups not different from controls (P > 0.05). In conclusion, we recommend expanding on these data to provide larger-scale studies.

scholarly journals Current approaches to treatment of antiphospholipid syndrome during pregnancy: a case report

2018 ◽  
Vol 67 (6) ◽  
pp. 100-105
Author(s):  
Ekaterina A. Kornyushina
Keyword(s):  
Deep Vein Thrombosis ◽  
Antiphospholipid Syndrome ◽  
Clinical Case ◽  
Standard Treatment ◽  
Recurrent Miscarriage ◽  
Vein Thrombosis ◽  
History Of ◽  
Deep Vein ◽  
Additional Therapy ◽  
In Pregnancy

The article presents a clinical case of a patient with antiphospholipid syndrome (APS), with a history of deep vein thrombosis and recurrent miscarriage. The methods of additional therapy for APS during pregnancy, which are used in cases of miscarriage refractory to the standard treatment, are described: administration of intravenous immunoglobulin, plasma exchange, glucocorticosteroids. The literature data on the use of additional APS therapy in pregnancy are given.

A murine model of deep vein thrombosis Characterization and validation in transgenic mice

2005 ◽  
Vol 94 (09) ◽  
pp. 498-503 ◽  
Author(s):  
Linda Szema ◽  
Chao-Ying Chen ◽  
Jeffrey P. Schwab ◽  
Gregory Schmeling ◽  
Brian C. Cooley
Keyword(s):  
Deep Vein Thrombosis ◽  
Murine Model ◽  
Femoral Vein ◽  
Previous History ◽  
Bed Rest ◽  
Major Surgery ◽  
Vein Thrombosis ◽  
Transgenic Lines ◽  
History Of ◽  
Deep Vein

SummaryDeep vein thrombosis (DVT) occurs with high prevalence in association with a number of risk factors, including major surgery, trauma, obesity, bed rest (>5 days), cancer, a previous history of DVT, and several predisposing prothrombotic mutations. A novel murine model of DVT was developed for applications to preclinical studies of transgenically constructed prothrombotic lines and evaluation of new antithrombotic therapies. A transient direct-current electrical injury was induced in the common femoral vein of adult C57Bl/6 mice. A non-occlusive thrombus grew, peaking in size at 30 min, and regressing by 60 min, as revealed by histomorphometric volume reconstruction of the clot. Pre-heparinization greatly reduced clot formation at 10, 30, and 60 min (p<0.01 versus non-heparinized). Homozygous FactorV Leiden mice (analogous to the clinical FactorV Leiden prothrombotic mutation) on a C57Bl/6 background had clot volumes more than twice those of wild-types at 30 min (0.121±0.018 mm3 vs. 0.052±0.008 mm3, respectively; p<0.01). Scanning electron microscopy revealed a clot surface dominated by fibrin strands, in contrast to arterial thrombi which showed a platelet-dominated structure. This new model of DVT presents a quantifiable approach for evaluating thrombosis-related murine transgenic lines and for comparatively evaluating new pharmacologic approaches for prevention of DVT.

scholarly journals History of COVID-19 infection is not associated with increased d-dimer levels and risk of deep-vein thrombosis in total joint arthroplasty

2021 ◽  
Author(s):  
Anna Jungwirth-Weinberger ◽  
Ilya Bendich ◽  
Carola Hanreich ◽  
Alejandro Gonzalez Della Valle ◽  
Jason L. Blevins ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Total Joint Arthroplasty ◽  
Joint Arthroplasty ◽  
Vein Thrombosis ◽  
History Of ◽  
Deep Vein ◽  
D Dimer
Sign in / Sign up

Export Citation Format

Share Document